ADMA Biologics Acquires Biotest’s Therapy Business Unit

ADMA Biologics, which develops, manufactures and commercializes specialty plasma-based biologics for the treatment of immune deficiencies and prevention of certain infectious diseases, has acquired Biotest Pharmaceuticals’ Therapy Business Unit (BTBU). As a result, ADMA has acquired Nabi-HB (hepatitis B immune globulin, human) and Bivigam (immune globulin intravenous, human), as well as the manufacturing and testing operations that consist of two facilities in Boca Raton, Fla. ADMA plans to file a biologics license application for its lead product candidate RI-002, a specialty plasma-derived, polyclonal, intravenous immune globulin to treat patients with primary immunodeficiency disease.